The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Progress in the treatment of Acute Promyelocytic Leukemia (APL) has changed course from a highly fatal to a highly curable disease with the use of novel drugs such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). The current risk stratification system has also led to dramatic improvement in managing the disease: nowadays, treatment regimens are different for low and high-risk groups.1 However, the clinical impact of Fms Like Tyrosine 3 Internal Tandem Duplication (FLT3-ITD) mutations remain controversial. In a recent issue of Hematology, Yingchao Fan et al. from Shidong Hospital, Shanghai, China, published results from their meta-analysis (MA) which investigated the clinical significance of FLT3-ITD mutation in patients with APL.
Using multiple online databases for the systematic review element of the MA, the authors identified 17 trials comprising of 2,252 APL patients. The identified studies used in this review focused on the relationship between FLT3-ITD and the Complete Remission (CR) rate, the 5-year Disease Free Survival (DFS) rate or the 5-year Overall Survival (OS) rate of adult APL. The treatment regimens in the identified 17 studies were comparable. All patients received standard chemotherapy, only the type of chemotherapy was somewhat different in each study. Patients were divided into two groups based on their mutational status; FLT3-ITD-positive group and FLT3-ITD-negative (FLT3-ITD-WT) group.
In conclusion, based on CR rate after induction therapy, 5-year OS, and 5-year DFS, the authors stated that FLT3-ITD positivity was likely to indicate poor prognosis in patients with APL.
Why did some other studies have a different conclusion? The authors added that “perhaps the treatment protocols affected the results. Although the treatment principle in all the trials was the same, drugs such as ATO added to induction therapy might improve survival”. They further added that the number of patients in this meta-analysis might not be sufficient enough and thus other on-going studies might lead to a change in the findings of this study.
References